ScienceAs China embraces AI, only 24% of US pharma executives bet on it for drug-making

Pharmaceutical companies have almost universally adopted artificial intelligence for drug research, but a Citi survey released Tuesday found that few executives expect it to produce successful medicines. Citi Asia healthcare research chief John Yung said the bigger risk is not slower discovery, but that faster development may fail to deliver better drugs or improve the odds of success.

artificial intelligencepharmaceuticalsdrug discovery

SSouth China Morning Post★★☆☆☆2026-09-09 06:00Original